Month: August 2025

Strengthening quarterly sales, up 13.5% from first quarter, with stronger gross margins of 23.5% after 2024 divestitures of previously consolidated international JVs AUBURN HILLS, Mich., Aug. 14, 2025 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR,” “SPAR Group” or the “Company”), a leading provider of merchandising, marketing, and distribution services, today reported financial and operating results for the three and six months ended June 30, 2025. Mike Matacunas, the Company’s President and Chief Executive Officer, commented, “Although the year-over-year comparisons of the consolidated financials remain complicated by the divestitures in the prior year, our second quarter revenues of $38.6 million for the continuing U.S. and Canada businesses were strong. U.S. and Canada revenues were up 5%1 compared to the prior year...

–  Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential Biologics License Application (BLA) filing; on track for potential data readout late 2026 –  FDA Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson’s disease –  In collaboration with Hologen, FDG-PET data from positive Phase 2 double-blind, sham-surgery controlled clinical trials of AAV-GAD shows significant disease-modifying effects in pathological basal ganglia circuitry, including the substantia nigra – the site of dopamine-producing neurons affected in Parkinson’s disease –  On track to file for Marketing Authorization Approval (MAA)...

VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”, “we” or “us”) (TSX: CFF) today reported results for the first quarter ended March 31, 2025. EBITDA* was negative $3.2 million for the quarter compared to EBITDA of $4.9 million in the first quarter of 2025 and negative $7.1 million in the second quarter of 2024. Net loss was $8.3 million or ($0.20) per share for the quarter versus net income of $0.6 million or $0.02 per share in the previous quarter and net loss of $9.7 million or ($0.24) per share in the second quarter of 2024. Selected Financial Highlights The following table summarizes our selected financial information for the comparative periods. The financial information reflects results of operations from our Mackenzie sawmill and power plant.Selected Financial Information              (unaudited,...

Second consecutive quarter with positive Adjusted EBITDA*, increasing year-to-date Adjusted EBITDA* to $0.6 million, representing a $0.1 million year-on-year improvement 6% quarter-over-quarter increase in revenue to $5.8 million Cash flows provided from operations of $0.2 million an improvement of $2.1 million year-on-yearBOCA RATON, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — SpringBig Holdings, Inc. OTCQB: SBIG (“Springbig” or the “Company”), a leading provider of AI powered MarTech solutions for regulated industries, today announced its financial results for the second quarter ended June 30, 2025. “Springbig’s new leadership team is executing with urgency and discipline, and the results are already showing,” said Jaret Christopher, CEO and Chairman of Springbig. “In Q2, we delivered tangible progress in our turnaround, with positive...

DOWNEY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company, announced its financial results for the second quarter ended June 30, 2025. We believe that Blüm has completed its turnaround and is now entering a disciplined growth phase aimed at expanding revenue, improving margins, controlling costs, and adding new locations without overextending capital. The Company believes that this strategy positions the Company to benefit from potential future changes to federal cannabis tax laws. Key Highlights from Second Quarter 2025Revenue increased from $2.2 million during Q1 2025 to $3.5 million in Q2 2025 driven by mid-quarter contributions from a newly added Bay Area retail location. Gross margin improved...

CALGARY, Alberta, Aug. 14, 2025 (GLOBE NEWSWIRE) — Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) (“Prospera”, “PEI” or the “Corporation”) In Q2 2025, Prospera invested $1.65 million in capital expenditures, including $665K for well reactivations, $534K for plant maintenance, and $448K for environmental work. Reactivation efforts targeted eleven wells in the Luseland and Cuthbert properties, adding 87 boe/d of production at an improved capital efficiency of $7,644/boe (vs. $9,317/boe in Q1). Plant maintenance improved infrastructure integrity, enhanced production reliability, and supported higher oil recovery. Strategic achievements included:Securing $3.2 million in additional term-debt advances for development and optimization. Completing workforce optimization to streamline decision-making and reduce G&A costs. Securing...

VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) has today filed its interim financial results for the second quarter ended June 30, 2025. All numbers are in U.S. dollars unless otherwise noted. Q2 2025 HIGHLIGHTS Entrée/Oyu Tolgoi Joint Venture Mining LicencesThe Joint Venture Agreement between the Company and Oyu Tolgoi LLC (“OTLLC”), with an effective date of June 30, 2008, as amended on February 3, 2025 (the “Entrée/Oyu Tolgoi JVA”), requires OTLLC, as Manager, to hold title to the Shivee Tolgoi and Javkhlant mining licences (the “Licences”) on behalf of the joint venture (“Entrée/Oyu Tolgoi JV”) participants. In February 2025, OTLLC and Entrée’s wholly owned subsidiary Entrée LLC duly executed and lodged License Transfer Agreements (the...

NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and six months ended June 30, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “We are encouraged by the continued analysis of data from our NAVIGATE trial , which further supports the clinical profile of belapectin in patients with MASH cirrhosis. At the European Association for the Study of the Liver (EASL) in May, we presented a clinically significant response in Fibroscan® (a key biomarker in MASH) and additional Fibroscan® data outcomes supporting the NAVIGATE trial’s primary endpoint, the prevention of esophageal varices after 18 months of treatment...

Implemented cost reductions extend cash runway into first half of 2027 BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today reported financial results as of and for the quarter ended June 30, 2025. The Company is actively evaluating opportunities to enhance the value of its pipeline programs. VYNE’s oral BD2-selective BET inhibitor, VYN202, has recently demonstrated a promising efficacy signal in a Phase 1b clinical trial in moderate to severe plaque psoriasis, as well as disease-modifying potential across multiple translational models of fibro-inflammatory disease and hematologic malignancies....

—Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug’s Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in PSC Featured at Multiple Major Scientific Meetings— —FDA and Chemomab Align on CMC and Non-Clinical Toxicology Regulatory Path Forward for Nebokitug—` —Cash Runway through End of Second Quarter of 2026— —Announces Plans to Implement ADS Ratio Change Adjustment— TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30,...